The study, sponsored by Johns Hopkins University, aimed to explore the potential of 7 Tesla MRI as a diagnostic tool for assessing myelin injury in ALS patients. Although the trial was withdrawn, the insights gained could inform future research and development in ALS diagnostics. The ALS market is characterized by a growing demand for innovative diagnostic techniques, particularly those that can predict disease progression. Companies focusing on neurodegenerative diseases may find strategic opportunities in developing imaging technologies or biomarkers that correlate with clinical outcomes, especially as the ALS patient population continues to seek effective management options.